Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Oxford BioMedica ( (GB:OXB) ) is now available.
Oxford Biomedica announced that Kay Davies, a Non-Executive Director, inadvertently purchased and then sold 4,563 shares due to an administrative error by her financial advisers. The transactions were reversed, and any gains from the trade will be donated to charity. This incident highlights the importance of compliance and transparency in financial dealings, reinforcing OXB’s commitment to regulatory standards.
The most recent analyst rating on (GB:OXB) stock is a Hold with a £532.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on GB:OXB Stock
According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.
Oxford BioMedica’s overall score reflects strong earnings call insights and positive corporate events, indicating strategic growth and leadership confidence. However, financial performance challenges and valuation concerns moderate the score.
To see Spark’s full report on GB:OXB stock, click here.
More about Oxford BioMedica
Oxford Biomedica (OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience in viral vectors, OXB collaborates with leading pharmaceutical and biotechnology companies to provide expertise in viral vector development and manufacturing. The company offers a range of technologies for viral vector manufacturing and operates facilities in the UK, France, and the US.
Average Trading Volume: 162,350
Technical Sentiment Signal: Buy
Current Market Cap: £536.3M
See more insights into OXB stock on TipRanks’ Stock Analysis page.